Teva settles in Israel on bribes
Teva has struck a settlement deal with Israeli authorities to end an investigation into “improper payments” relating to the firm’s operations in Mexico, Russia and Ukraine. The investigation related to activities – including bribing government officials – that ended in 2012 and over which Teva agreed a US$519 million US settlement more than a year ago (Generics bulletin, 6 January 2017, page 3).
You may also be interested in...
Viatris’ Mylan has accused Teva of creating a perfect ‘playbook’ to delay Mylan’s launch of a generic version of its Copaxone blockbuster and then strangle uptake, something Mylan was vocal about years earlier, in a suit filed in a New Jersey court.
The Cincinnati, OH-based firm will pay $8m to recompense Unites States residents who purchased aerosol personal-care products potentially contaminated with benzene over a roughly six-year period.
An independent review of the US FDA’s food regulatory programs could renew a debate over splitting FDA into two agencies. That could be a distraction for the agency in the coming year – but it could also help keep the medical product review groups out of the political hot seat.